These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 16879623

  • 1. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.
    Mullen AB, Lawrence CE, McFarlane E, Wei XQ, Carter KC.
    Immunology; 2006 Nov; 119(3):348-54. PubMed ID: 16879623
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
    Bimal S, Sinha S, Singh SK, Narayan S, Kumar V, Verma N, Ranjan A, Sinha PK, Das VN, Pandey K, Kar SK, Das P.
    Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.
    Lehmann J, Enssle KH, Lehmann I, Emmendörfer A, Lohmann-Matthes ML.
    J Interferon Cytokine Res; 2000 Jan; 20(1):63-77. PubMed ID: 10670653
    [Abstract] [Full Text] [Related]

  • 6. Studies on the protective efficacy of second-generation vaccine along with standard antileishmanial drug in Leishmania donovani infected BALB/c mice.
    Joshi J, Kaur S.
    Parasitology; 2014 Apr; 141(4):554-62. PubMed ID: 24618257
    [Abstract] [Full Text] [Related]

  • 7. Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody.
    Nabors GS, Farrell JP.
    Am J Trop Med Hyg; 1995 Jul; 53(1):55-60. PubMed ID: 7625533
    [Abstract] [Full Text] [Related]

  • 8. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
    Narayan S, Bimal S, Singh SK, Gupta AK, Singh VP, Sinha PK, Das P.
    Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
    [Abstract] [Full Text] [Related]

  • 9. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
    Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A.
    J Immunol; 2011 Dec 15; 187(12):6417-27. PubMed ID: 22079980
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
    Bhaumik SK, Naskar K, De T.
    Eur J Immunol; 2009 Aug 15; 39(8):2146-60. PubMed ID: 19593771
    [Abstract] [Full Text] [Related]

  • 12. [TH1 response in the experimental infection with Trypanosoma cruzi].
    Cardoni RL, Antúnez MI, Abrami AA.
    Medicina (B Aires); 1999 Aug 15; 59 Suppl 2():84-90. PubMed ID: 10668248
    [Abstract] [Full Text] [Related]

  • 13. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
    Mazumdar T, Anam K, Ali N.
    Vaccine; 2004 Mar 12; 22(9-10):1162-71. PubMed ID: 15003644
    [Abstract] [Full Text] [Related]

  • 14. Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy.
    Carter KC, Hutchison S, Boitelle A, Murray HW, Sundar S, Mullen AB.
    Parasitology; 2005 Dec 12; 131(Pt 6):747-57. PubMed ID: 16336728
    [Abstract] [Full Text] [Related]

  • 15. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
    Gupta R, Kushawaha PK, Samant M, Jaiswal AK, Baharia RK, Dube A.
    J Antimicrob Chemother; 2012 Feb 12; 67(2):440-3. PubMed ID: 22121191
    [Abstract] [Full Text] [Related]

  • 16. The IL-33/ST2 axis is associated with human visceral leishmaniasis and suppresses Th1 responses in the livers of BALB/c mice infected with Leishmania donovani.
    Rostan O, Gangneux JP, Piquet-Pellorce C, Manuel C, McKenzie AN, Guiguen C, Samson M, Robert-Gangneux F.
    mBio; 2013 Sep 17; 4(5):e00383-13. PubMed ID: 24045639
    [Abstract] [Full Text] [Related]

  • 17. Therapy with sodium stibogluconate in stearylamine-bearing liposomes confers cure against SSG-resistant Leishmania donovani in BALB/c mice.
    Roychoudhury J, Sinha R, Ali N.
    PLoS One; 2011 Mar 10; 6(3):e17376. PubMed ID: 21423750
    [Abstract] [Full Text] [Related]

  • 18. Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection.
    Henriquez FL, Campbell SA, Roberts CW, Mullen AB, Burchmore R, Carter KC.
    J Parasitol; 2010 Oct 10; 96(5):929-36. PubMed ID: 20950100
    [Abstract] [Full Text] [Related]

  • 19. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
    Bhowmick S, Ravindran R, Ali N.
    Vaccine; 2007 Aug 29; 25(35):6544-56. PubMed ID: 17655984
    [Abstract] [Full Text] [Related]

  • 20. IL-12 enhances Th1-type responses in human Leishmania donovani infections.
    Ghalib HW, Whittle JA, Kubin M, Hashim FA, el-Hassan AM, Grabstein KH, Trinchieri G, Reed SG.
    J Immunol; 1995 May 01; 154(9):4623-9. PubMed ID: 7722314
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.